HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

8-(4-sulfophenyl)theophylline

adenosine antagonist
Also Known As:
8-(p-sulfophenyl)theophylline; 8-PSPT; 8-sulfophenyltheophylline; 8-sulphophenyltheophylline; PSP-theophylline; Benzenesulfonic acid, 4-(2,3,6,7-tetrahydro-1,3-dimethyl-2,6-dioxo-1H-purin-8-yl)-
Networked: 40 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Asanuma, Hiroshi: 3 articles (10/2004 - 01/2002)
2. Hori, Masatsugu: 3 articles (10/2004 - 01/2002)
3. Kitakaze, Masafumi: 3 articles (10/2004 - 01/2002)
4. Node, Koichi: 3 articles (10/2004 - 01/2002)
5. Sanada, Shoji: 3 articles (10/2004 - 01/2002)
6. Takashima, Seiji: 3 articles (10/2004 - 01/2002)
7. Asano, Yoshihiro: 2 articles (10/2004 - 06/2004)
8. Kim, Jiyoong: 2 articles (10/2004 - 06/2004)
9. Kitamura, Soichiro: 2 articles (10/2004 - 06/2004)
10. Minamino, Tetsuo: 2 articles (10/2004 - 06/2004)

Related Diseases

1. Infarction (Infarctions)
02/01/2014 - "Administration of adenosine receptor blocker 8-(p-sulfophenyl)theophylline abolished the infarct limiting effect (46 ± 7 %) and the mitochondrial integrity and function preservation of IPC effluent. "
03/01/1996 - "When 8-(p-sulfophenyl)theophylline (100 microM), which prevents the infarct size-limiting effect of ischemic preconditioning by blocking adenosine receptors was present in the perfusate, the pattern of purine release was not altered (151 +/- 13 nmol/g during the first minute after the first 5-min ischemic episode dropping to 117 +/- 6 nmol/g after the second ischemic period P < 0.05). "
01/01/1997 - "8-Sulfophenyltheophylline (an antagonist of adenosine receptors) or alpha,beta-methyleneadenosine 5'-diphosphate (an inhibitor of ecto-5'-N) eliminated the cardioprotective effect of the PKC activator (infarct size: 36.6 +/- 3.9 and 34.7 +/- 4.2%, respectively), suggesting that PMA limits infarct size by increasing the activity of ecto-5'-N and the adenosine level. "
10/12/2004 - "The magnitude of the infarct-limiting effect paralleled the increase in Akt and ecto-5'-nucleotidase activity and was blunted by administration of wortmannin, alpha,beta-methyleneadenosine-5'-diphosphate, or 8-sulfophenyltheophylline during reperfusion. "
06/08/2004 - "Carvedilol reduced the infarct size (15.0+/-2.8% versus 40.9+/-4.2% in controls), and this effect was completely reversed by the nonselective adenosine receptor antagonist 8-sulfophenyltheophylline (45.2+/-5.4%) or by an inhibitor of ecto-5'-nucleotidase (44.4+/-3.6%). "
2. Seizures (Absence Seizure)
3. Ischemia
4. Hyperemia
5. Hypoxia (Hypoxemia)
11/01/1996 - "Adenosine receptor antagonist 8-sulfophenyltheophylline (8-SPT) blocked the protective effect of preconditioning hypoxia. "
08/01/1993 - "Systemic hypoxia (PaO2 = 24 +/- 1 mm Hg; n = 8) or hemorrhagic hypotension (MABP = 41 +/- 1 mm Hg; n = 5) was induced, and the effect of intravitreal microsuffusion of 0.4 nmol of the adenosine receptor antagonist 8-sulfophenyltheophylline (8SPT) on retinal arteriolar dilations resulting from these stimuli were measured. "
07/01/1993 - "When hearts were subjected to hypoxia in the presence of ADO deaminase, theophylline, or 8-(p-sulfophenyl)theophylline, the hypoxia-induced bradycardia was blocked in the GP hearts and either slightly reduced or not affected in muskrat hearts. "
12/01/1997 - "The cellular viability of HCAEC exposed to 60 min of hypoxia and 60 min of reoxygenation increased from 34+/-5 to 67+/-6% (Trypan blue exclusion test) and 23+/-5 to 78+/-6% (LDH release), which was completely blunted by 8-sulfophenyltheophylline, an adenosine receptor antagonist, and was partially blunted by alpha,beta-methyleneadenosine 5'-diphosphate, an inhibitor of ecto-5'-nucleotidase. "
09/01/1994 - "In two groups of Saffan-anaesthetized, spontaneously breathing rats we have attempted to identify the peripheral influences of adenosine in mediating the responses evoked by hypoxia by using an adenosine receptor antagonist, 8-sulphophenyltheophylline (8-SPT, 20 mg kg-1 i.v., Group 1) and adenosine deaminase (ADA, 500 units in 0.04 ml infused into the tail artery for 10 min, Group 2); neither of these drugs crosses the blood-brain barrier. "

Related Drugs and Biologics

1. Purinergic P1 Receptors (Adenosine Receptor)
2. Adenosine (Adenocard)
3. Purinergic P1 Receptor Antagonists
4. alpha,beta-methyleneadenosine 5'-diphosphate
5. Adenosine-5'-(N-ethylcarboxamide) (NECA)
6. NG-Nitroarginine Methyl Ester (L-NAME)
7. Nitric Oxide Synthase (NO Synthase)
8. Cyclooxygenase Inhibitors
9. Indomethacin (Indometacin)
10. Glyburide (Glibenclamide)

Related Therapies and Procedures

1. Intra-Arterial Injections